Clinical trials: Head and Neck Cancers- Squamous Cell
Esophageal Cancer, Gastric Cancer
S0101 Gemcitabine and Irinotecan in Treating Patients With Metastatic or Recurrent Cancer of the Esophagus
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00012363
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- 96 sites in United States
- Volunteers
- 61 people
- Sponsor
- SWOG Cancer Research Network
Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma
Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease
Immunotherapy has become the standard of care in different advanced malignancies. Its effectiveness in the palliative setting was demonstrated by several phase III trials.
- Conditions
- Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Melanoma, Urothelial Carcinoma
- Trial name
- ICONIC (NCT05229614)
- Testing
- Carbon Ion Therapy, Immunotherapy (Pembrolizumab)
- Where
- 4 sites in Germany, Italy
- Volunteers
- 27 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Solid Tumors
Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)
This is a Phase 1, open-label, dose-escalation trial of avelumab [antibody targeting programmed death ligand 1 (anti PD-L1)] with consecutive parallel group expansion in participants with selected tumor indications.
- Trial name
- NCT01772004
- Testing
- Avelumab
- Where
- 74 sites in United States, Belgium and 7 more
- Volunteers
- 1,756 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Esophageal Squamour Cell Cancer
Neoadjuvant Ivonescimab and Chemotherapy in Resectable Esophageal Cancer
Neoadjuvant ChemoRadioTherapy (NCRT) combined with surgical resection is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC) based on CROSS and 5010 study.
- Trial name
- NCT06814158
- Testing
- Ivonescimab Combined With Chemotherapy
- Where
- China
- Volunteers
- 57 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Oral Squamous Cell Carcinoma, Head and Neck Cancer
Neoadjuvant Presurgical Becotatug Vedotin (MRG003) Plus Pucotenlimab (HX008) in Oral Cavity Squamous Cell Carcinoma
This is a phase 2, open-label, single-arm clinical trial evaluating neoadjuvant therapy with Becotatug vedotin (MRG003) combined with Pucotenlimab (HX008) in patients with previously untreated, resectable stage III-IVA oral…
- Conditions
- Oral Squamous Cell Carcinoma, Head and Neck Cancer, Locally Advanced Head and Neck Cancer, Neoadjuvant Therapy
- Trial name
- NCT07766889
- Testing
- Becotatug Vedotin (MRG003), Pucotenlimab
- Where
- 2 sites in China
- Volunteers
- 32 people
- Sponsor
- Sun Yat-sen University
Melanoma, Head and Neck Cancer
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
The purpose of this study is to evaluate the safety of enoblituzumab (MGA271) in combination with Keytruda (pembrolizumab) when given to patients with B7-H3-expressing melanoma, squamous cell carcinoma of the head and neck…
- Conditions
- Melanoma, Head and Neck Cancer, Non Small Cell Lung Cancer, Urothelial Carcinoma
- Trial name
- NCT02475213
- Testing
- Enoblituzumab Schedule 1, Pembrolizumab, Enoblituzumab Schedule 2
- Where
- 20 sites in United States
- Volunteers
- 146 people
- Sponsor
- MacroGenics
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
Priming Immunotherapy in Advanced Disease With Radiation
This study proposes to treat metastatic non-small cell lung cancer (NSCLC) and head/neck squamous cell cancer (HNSCC) patients who are already initiating an immune checkpoint inhibitor (such as Nivolumab, Atezolizumab or…
- Trial name
- NCT03313804
- Testing
- Immune checkpoint inhibitor, Radiation Therapy
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- John L. Villano, MD, PhD
Oesophageal Adenocarcinoma, Squamous Cell Carcinoma
M6620 Plus Standard Treatment in Oesophageal and Other Cancer
This Phase I study will test the combination of a novel ATR inhibitor (M6620) with chemoradiotherapy in oesophageal cancer; utilizing three experimental cohorts (Stage A1, A2 and B).
- Conditions
- Oesophageal Adenocarcinoma, Squamous Cell Carcinoma, Solid Tumor
- Trial name
- CHARIOT (NCT03641547)
- Testing
- M6620, Cisplatin, Capecitabine
- Where
- 5 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- University of Oxford
Oropharyngeal Squamous Cell Carcinoma, Human Papillomavirus (HPV)
The Role of Circulating Tumour DNA in Head and Neck Cancer
Cancers of the throat, oropharyngeal squamous cell carcinoma (OPSCC), are highly prevalent across Scotland. Over the past 10 years, both global and Scottish cases of OPSCC have increased, particularly those associated with human…
- Trial name
- NCT05539638
- Where
- 5 sites in United Kingdom
- Volunteers
- 250 people
- Sponsor
- University of Edinburgh
Head and Neck Cancer
Everolimus Versus Placebo in Head and Neck Cancer
Primary: Two-year progression-free (tumor does not grow or spread) survival in subjects treated with everolimus versus placebo after definitive local therapy.
- Trial name
- NCT01111058
- Testing
- Everolimus (RAD 001)
- Where
- 17 sites in United States
- Volunteers
- 52 people
- Sponsor
- University of Chicago
Head and Neck Squamous Cell Carcinoma HNSCC
Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial
This study compares two short pre-surgery treatments for locally advanced head and neck squamous cell cancer to see which one keeps the cancer from coming back longer.
- Trial name
- SHINE (NCT07371897)
- Testing
- Docetaxel and Cisplatin, Toripalimab
- Volunteers
- 154 people
- Sponsor
- Sun Yat-sen University
Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
Cisplatin Combined With S-1 or Paclitaxel as First-line Treatment for Metastatic Esophageal Squamous Cell Carcinoma
- Trial name
- NCT02677597
- Testing
- Cisplatin Combined With S-1, Cisplatin Combined With Paclitaxel
- Where
- China
- Volunteers
- 268 people
- Sponsor
- Fudan University
HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer
Therapy for High-Risk HPV 16-Positive Oropharynx Cancer Patients
Combination immune checkpoint inhibitor and DNA vaccine will result in clearance of HPV DNA biomarkers (oral and/or plasma) for patients with persistent HPV-16 E6/E7 DNA (HPV biomarker) after treatment with curative intent.
- Conditions
- HPV Positive Oropharyngeal Squamous Cell Carcinoma, Oropharynx Cancer, HPV-Related Carcinoma
- Trial name
- NCT04001413
- Testing
- MEDI0457, Durvalumab
- Where
- 4 sites in United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Esophageal Squamous Cell Carcinoma
Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial
The investigators will assess the adequacy of nodal dissection along the recurrent laryngeal nerve performed with robot-assisted versus video-assisted thoracoscopic esophagectomy in patients with esophageal squamous cell…
- Trial name
- NCT03713749
- Testing
- Robot esophagectomy (RE)
- Where
- Taiwan
- Volunteers
- 212 people
- Sponsor
- Chang Gung Memorial Hospital
Bronchial Dysplasia, Tobacco Smoking
Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers
The goal of this clinical research study is to determine whether the PD-1 inhibitor (Programmed cell death protein 1) nivolumab improves premalignant bronchial dysplastic lesions in subjects that are at high risk for the…
- Conditions
- Bronchial Dysplasia, Tobacco Smoking, History of Non-Small Cell Lung Cancer, History of Head and Neck Cancer
- Trial name
- NCT03347838
- Testing
- Nivolumab
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- University of Colorado, Denver
Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy
Neoadjuvant PD-1 Inhibitor Combined With Cetuximab in Operable Locally Advanced HNSCC
This is a single-center, single-arm, phase II clinical study to evaluate the efficacy and safety of PD-1 inhibitor combined with cetuximab in neoadjuvant therapy for locally advanced HNSCC.
- Trial name
- PC-1 (NCT05993858)
- Testing
- 3cycles (Toripalimab + cetuximab), Surgery, Radiotherapy or chemoradiotherapy
- Where
- China
- Volunteers
- 33 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Head and Neck Squamous Cell Carcinoma (HNSCC), Locally Advanced Head and Neck Squamous Cell Carcinoma
[18F]-AraG PET Imaging in LA HNSCC
This study will use [18F]-AraG PET/CT scans to monitor patients who have been diagnosed with locally advanced Head and Neck Squamous Cell carcinoma (LA-HNSCC), and are planning to undergo standard of care chemoradiotherapy for…
- Trial name
- NCT07168785
- Testing
- [18F]-AraG radiotracer, Chemotherapy, Radiotherapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Indiana University
Head and Neck Cancer, Oropharyngeal Carcinoma
Thermotherapy for Head and Neck Cancer Patients
This phase I, single-center study evaluates the safety, tolerability, and recommended phase II dose (RP2D) of mild hyperthermia (thermotherapy) when added to standard-of-care treatment in patients with locally advanced head and…
- Conditions
- Head and Neck Cancer, Oropharyngeal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma
- Trial name
- TANCAP-I (NCT07690618)
- Testing
- Thermotherapy, Radiotherapy, Concurrent chemoradiation
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Erasmus Medical Center
Solid Tumors
DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
- Trial name
- NCT06953089
- Testing
- DB-1311/BNT324, BNT327, DB-1305/BNT325
- Where
- 37 sites in United States, Australia and 2 more
- Volunteers
- 750 people
- Sponsor
- DualityBio Inc.
Epithelial Ovarian Cancer, Gastric Adenocarcinoma
Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)
A Phase I-II, First-in-Human Study of SKB264 (Sac-TMT; MK-2870) in Patients with Locally Advanced Unresectable/Metastatic Solid Tumors who are refractory to Available Standard Therapies.
- Conditions
- Epithelial Ovarian Cancer, Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Urothelial Carcinoma
- Trial name
- MK-2870-001 (NCT04152499)
- Testing
- SKB264
- Where
- 109 sites in United States, Canada and 4 more
- Volunteers
- 1,410 people
- Sponsor
- Klus Pharma Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.